Mylan Laboratories, along with Aurobindo Pharma, received support from the foundation to expand the distribution of a single-pill HIV treatment containing dolutegravir to low- and middle-income populations at a low price. This treatment is part of a global effort to provide everyone living with HIV with high-quality antiretroviral therapy.
Investment Date: July 2017